Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Muthu Veeraputhiran

Concepts (120)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hematopoietic Stem Cell Transplantation
9
2023
578
1.990
Why?
Hematologic Neoplasms
2
2021
99
0.790
Why?
Blood Platelets
3
2011
251
0.680
Why?
Transplantation Conditioning
2
2017
87
0.660
Why?
Hematopoietic Stem Cells
2
2011
197
0.650
Why?
Comorbidity
1
2017
623
0.490
Why?
Graft vs Host Disease
3
2023
84
0.460
Why?
Melphalan
1
2015
178
0.460
Why?
Leukocytes
2
2011
69
0.450
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2014
56
0.450
Why?
Granulocyte Colony-Stimulating Factor
1
2014
63
0.450
Why?
Hematopoietic Stem Cell Mobilization
1
2014
58
0.450
Why?
Cyclophosphamide
1
2014
168
0.430
Why?
Hemagglutination Tests
1
2011
7
0.380
Why?
Aldehyde Dehydrogenase
1
2011
25
0.380
Why?
Isoantibodies
1
2011
29
0.380
Why?
Transplantation, Autologous
4
2015
481
0.360
Why?
Plateletpheresis
1
2010
7
0.360
Why?
Blood Preservation
1
2010
26
0.360
Why?
Cryopreservation
1
2010
33
0.350
Why?
Blood Proteins
1
2010
84
0.340
Why?
Anaphylaxis
1
2010
69
0.340
Why?
Graft vs Leukemia Effect
1
2009
3
0.340
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2009
45
0.330
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2015
1000
0.320
Why?
Rhabdomyolysis
1
2008
12
0.300
Why?
Anticholesteremic Agents
1
2008
27
0.300
Why?
Simvastatin
1
2008
29
0.300
Why?
Quinazolines
1
2008
32
0.300
Why?
Multiple Myeloma
2
2015
2998
0.300
Why?
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
2024
11
0.290
Why?
Protein Kinase Inhibitors
1
2008
204
0.270
Why?
Immunotherapy, Adoptive
2
2024
163
0.260
Why?
Antibodies, Monoclonal
1
2009
462
0.250
Why?
Pyrazoles
2
2023
111
0.250
Why?
Aged
8
2024
9741
0.240
Why?
Humans
17
2024
50503
0.240
Why?
Neoplasm Recurrence, Local
2
2024
629
0.230
Why?
Time Factors
1
2010
2935
0.230
Why?
Acetamides
1
2023
18
0.220
Why?
Platelet Transfusion
2
2015
29
0.210
Why?
Adult
8
2024
13577
0.210
Why?
Retrospective Studies
6
2024
6263
0.210
Why?
Middle Aged
7
2024
12611
0.210
Why?
Antigens, CD34
2
2011
75
0.180
Why?
Cell Count
2
2011
150
0.180
Why?
Graft Survival
2
2011
159
0.170
Why?
Heart Rate
1
2021
307
0.170
Why?
Cell Survival
2
2011
589
0.160
Why?
Liver Transplantation
1
2020
154
0.150
Why?
Incidence
1
2021
1032
0.150
Why?
Cytomegalovirus Infections
1
2017
38
0.140
Why?
Transplantation, Homologous
1
2017
145
0.140
Why?
Appendicitis
1
2017
61
0.140
Why?
Regression Analysis
1
2017
382
0.130
Why?
Young Adult
3
2024
4102
0.130
Why?
Antineoplastic Agents, Alkylating
1
2016
73
0.130
Why?
Female
7
2024
27081
0.130
Why?
Dendritic Cells
1
2016
135
0.120
Why?
Carmustine
1
2015
14
0.120
Why?
Postoperative Hemorrhage
1
2015
52
0.120
Why?
Cytarabine
1
2015
37
0.120
Why?
Etoposide
1
2015
77
0.120
Why?
Bronchoscopy
1
2015
73
0.120
Why?
Thrombocytopenia
1
2015
81
0.120
Why?
Survival Rate
1
2017
909
0.120
Why?
Salvage Therapy
1
2015
137
0.120
Why?
Drug Substitution
1
2014
9
0.110
Why?
Disease-Free Survival
1
2015
444
0.110
Why?
Drug Evaluation
1
2014
28
0.110
Why?
Blood Cell Count
1
2014
39
0.110
Why?
Benzylamines
1
2014
15
0.110
Why?
Heterocyclic Compounds
1
2014
29
0.110
Why?
Male
7
2024
25907
0.110
Why?
Drug Synergism
1
2014
151
0.110
Why?
Risk Assessment
1
2017
1270
0.100
Why?
Nitriles
2
2023
52
0.100
Why?
Prognosis
1
2017
1978
0.100
Why?
Immune Tolerance
1
2011
84
0.090
Why?
Skin Neoplasms
1
2016
491
0.090
Why?
Dimethyl Sulfoxide
1
2010
13
0.090
Why?
Pyrimidines
2
2023
191
0.090
Why?
Isotonic Solutions
1
2010
17
0.090
Why?
P-Selectin
1
2010
32
0.090
Why?
Sodium Chloride
1
2010
55
0.090
Why?
Platelet Aggregation
1
2010
70
0.090
Why?
Platelet Activation
1
2010
45
0.090
Why?
Hypersensitivity
1
2010
75
0.080
Why?
Feasibility Studies
1
2011
390
0.080
Why?
Sensitivity and Specificity
1
2011
859
0.080
Why?
Atenolol
1
2008
13
0.080
Why?
Azetidines
1
2008
6
0.080
Why?
Amlodipine
1
2008
13
0.080
Why?
Anti-Inflammatory Agents
1
2009
163
0.080
Why?
Hyperlipidemias
1
2008
52
0.070
Why?
Drug Interactions
1
2008
206
0.070
Why?
Tumor Necrosis Factor-alpha
1
2009
393
0.070
Why?
Antihypertensive Agents
1
2008
125
0.070
Why?
Aspirin
1
2008
112
0.070
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2008
121
0.070
Why?
Carcinoma, Non-Small-Cell Lung
1
2008
154
0.070
Why?
Antigens, CD19
1
2024
29
0.060
Why?
Coronary Artery Disease
1
2008
278
0.060
Why?
Treatment Outcome
2
2024
5283
0.060
Why?
Adolescent
2
2024
6443
0.050
Why?
Hypertension
1
2008
544
0.050
Why?
Tomography, X-Ray Computed
1
2008
1164
0.050
Why?
Lung Neoplasms
1
2008
601
0.050
Why?
Chronic Disease
1
2023
573
0.050
Why?
Child
1
2011
6906
0.040
Why?
Ganciclovir
1
2017
25
0.040
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2017
81
0.030
Why?
Antiviral Agents
1
2017
170
0.030
Why?
Platelet Count
1
2015
65
0.030
Why?
Leukemia, Myeloid, Acute
1
2016
181
0.030
Why?
Bone Marrow
1
2016
363
0.030
Why?
Biopsy
1
2016
588
0.030
Why?
Practice Guidelines as Topic
1
2015
468
0.030
Why?
Antineoplastic Agents
1
2017
1172
0.020
Why?
Aged, 80 and over
1
2015
3226
0.020
Why?
Veeraputhiran's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description